Find Baricitinib manufacturers, exporters & distributors on PharmaCompass

Baricitinib

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

28 API Suppliers, 5 USDMF, 8 KDMF, 3 NDC API, 25 Listed Suppliers, $ API Reference Price

28 API Suppliers
5 USDMF
8 KDMF
3 NDC API
25 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

46 Drugs in Development

46 Drugs in Development

INTERMEDIATES

19 Intermediates Suppliers

19 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

20 FDF Dossiers, 5 FDA Orange Book, 2 Europe, 2 Canada, 6 Australia, 2 South Africa, 3 Listed Dossiers

20 FDF Dossiers
5 FDA Orange Book
2 Europe
2 Canada
6 Australia
2 South Africa
3 Listed Dossiers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 144 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
144 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 2 Finished Drug Prices, 5 Annual Reports

globalSalesInformation
1 US Medicaid Prescriptions
2 Finished Drug Prices
5 Annual Reports

MARKET PLACE

15 APIs, 2 FDF Dossiers

marketPlace
15 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

17 US Patents, 6 US Exclusivities

patents
17 US Patents
6 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

144

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

21,134,588

Annual Reports (USD Million)

3,935

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1187594-09-7, Olumiant, Incb028050, Ly3009104, 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, Incb 028050

Molecular Formula

C₁₆H₁₇N₇O₂S

Molecular Weight

371.4 g/mol

InChI Key

XUZMWHLSFXCVMG-UHFFFAOYSA-N

FDA UNII

ISP4442I3Y

Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.

Baricitinib is a Janus Kinase Inhibitor. The mechanism of action of baricitinib is as a Janus Kinase Inhibitor.

1 2D Structure

Baricitinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile

2.1.2 InChI

InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)

2.1.3 InChI Key

XUZMWHLSFXCVMG-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

2.2 Other Identifiers

2.2.1 UNII

ISP4442I3Y

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-

2. 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-, Phosphate (1:1)

3. Baricitinib Phosphate

4. Baricitinib Phosphate Salt

5. Incb-028050

6. Incb-28050

7. Incb028050

8. Ly-3009104

9. Ly3009104

10. Olumiant

2.3.2 Depositor-Supplied Synonyms

1. 1187594-09-7

2. Olumiant

3. Incb028050

4. Ly3009104

5. 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

6. Incb 028050

7. Incb-028050

8. Ly-3009104

9. 1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-3-azetidineacetonitrile

10. Baricitinib (ly3009104, Incb028050)

11. 2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile

12. Isp4442i3y

13. Ly 3009104

14. 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-

15. Ly3009104 (phosphate);incb028050 (phosphate)

16. Incb28050

17. Baricitinib [usan]

18. Baricitinib [usan:inn]

19. Unii-isp4442i3y

20. Incb 28050

21. Olumiant (tn)

22. 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-

23. 3jw

24. Baricitinib [mi]

25. Baricitinib [inn]

26. Baricitinib [jan]

27. Baricitinib [who-dd]

28. Mls006011247

29. Schembl871150

30. Baricitinib (jan/usan/inn)

31. Baricitinib (ly3009104)

32. Baricitinib [ema Epar]

33. Baricitinib (incb028050)

34. Gtpl7792

35. Chembl2105759

36. Ammd00005

37. Chebi:95341

38. Baricitinib [orange Book]

39. Dtxsid30152228

40. Ex-a413

41. Hms3651l17

42. Hms3672m15

43. Hms3747g21

44. Bcp04686

45. Bdbm50021656

46. Mfcd21608464

47. Nsc799357

48. S2851

49. Zinc73069247

50. Akos022186127

51. Akos025401933

52. Am81232

53. Bcp9000380

54. Ccg-268312

55. Cs-0724

56. Db11817

57. Ds-7641

58. Nsc-799357

59. Pb27275

60. Sb10845

61. Ncgc00345839-01

62. Ncgc00345839-14

63. Ncgc00345839-16

64. 2-(3-(4-(3h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

65. Ac-27404

66. Hy-15315

67. Smr004703006

68. Bcp0726000031

69. Baricitinib (incb28050, Ly3009104)

70. Ft-0775037

71. Sw220096-1

72. D10308

73. A892931

74. J-503551

75. Q4860707

76. (1-(ethylsulfonyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)azetidin-3-yl)ethanenitrile

77. {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile

78. Incb 28050; Incb28050; Ly-3009104;1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-3-azetidineacetonitrile

2.4 Create Date

2009-09-28

3 Chemical and Physical Properties

Molecular Formula	C₁₆H₁₇N₇O₂S
Molecular Weight	371.4 g/mol
XLogP3	-0.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	5
Exact Mass	371.11644398 g/mol
Monoisotopic Mass	371.11644398 g/mol
Topological Polar Surface Area	129 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	678
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.

FDA Label

Rheumatoid arthritis

Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.

Atopic Dermatitis

Baricitinib is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.

Alopecia areata

Baricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. 1).

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis , ankylosing spondylarthritis , psoriatic arthritis and juvenile idiopathic arthritis )

Treatment of Systemic Lupus Erythematosus (SLE)

Treatment of Coronavirus disease 2019

Treatment of alopecia areata

Treatment of atopic dermatitis

5 Pharmacology and Biochemistry

5.1 FDA Pharmacological Classification

5.1.1 Active Moiety

BARICITINIB

5.1.2 FDA UNII

ISP4442I3Y

5.1.3 Pharmacological Classes

Janus Kinase Inhibitors [MoA]; Janus Kinase Inhibitor [EPC]

5.2 ATC Code

L04AA37

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

L - Antineoplastic and immunomodulating agents

L04 - Immunosuppressants

L04A - Immunosuppressants

L04AA - Selective immunosuppressants

L04AA37 - Baricitinib

5.3 Absorption, Distribution and Excretion

Absorption

Baricitinib diaplays a dose-proportional increase in systemic exposure in the therapeutic dose range with linear pharmacokinetics. When orally administered, baricitinb is rapidly absorbed with an oral bioavailability of approximately 79 % (CV = 3.94 %). It has a median time to reach peak plasma concentration (Tmax) of 1hour (range: 0.5-3hours). Food consumption affects the exposure by decreasing it by up to 14 %, and decreasing the peak plasma concentration (Cmax) by up to 18 % and Tmax by 0.5 hours.

Route of Elimination

In a clinical pharmacology study, baricitinib was excreted predominately as the unchanged active substance in urine (69 %) and feces (15 %) and only 4 minor oxidative metabolites were identified (3 in urine; 1 in feces) constituting approximately 5 % and 1 % of the dose, respectively.

Volume of Distribution

Mean volume of distribution following intravenous infusion administration is 76 L.

Clearance

Mean apparent clearance (CL/F) in patients with rheumatoid arthritis is approximately 9.42 L/hr (CV = 34.3 %).

5.4 Metabolism/Metabolites

Baricitinib undergoes oxidation by CYP3A4, although less than 10% of the total dose is prone to this biotransformation. There is no formation of quantifiable metabolites in the plasma.

5.5 Biological Half-Life

Mean half-life in patients with rheumatoid arthritis is approximately 12.5 hrs (CV = 27.4 %).

5.6 Mechanism of Action

JAK enzymes are part of the family of tyrosine kinases that constitutively bind to the intracellular domains of cytokine receptors and promote the signalling cascades of cytokines and growth factors involved in haematopoiesis, inflammation and immune function that are also implicated in the pathogenesis of rheumatoid arthritis. Circulating proinflammatory cytokines bind to these cell surface receptors. Upon binding of extracellular cytokines and growth factors, JAKs are phosphorylated and activate signal transducers and activators of transcription (STATs). Through the signalling cascades, inflammatory cytokine and chemokine transcription is induced to form inflammatory mediators including IL-2, IL-6, IL-12, IL-15, IL-23, IFN- and GM-CSF. Baricitinib selectively and reversibly inhibits JAK1 and JAK2 to modulates their signalling pathways, thereby reducing the phosphorylation and activation of STATs. In isolated enzyme assays, baricitinib also exhibited an inhibitory effect on other types of JAK enzymes,Tyrosine Kinase 2 and JAK3, at higher concentrations needed for JAK1/2 inhibition.

API SUPPLIERS

01

Polpharma

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

American Pharma Summit

Not Confirmed

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Poland

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

American Pharma Summit

Not Confirmed

TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

03

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioFlorida Conference

Attending

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

04

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmtech & Ingredients

Exhibiting

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

05

Tofigh Daru

Iran

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmtech & Ingredients

Attending

Tofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.

Contact Supplier

Iran

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

06

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

American Pharma Summit

Not Confirmed

Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Contact Supplier

Taiwan

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

07

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India 2024

Attending

Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

08

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

American Pharma Summit

Not Confirmed

09

Nanjing Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

American Pharma Summit

Not Confirmed

10

Wisdom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

American Pharma Summit

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Chunghwa Chemical Synthesis And Biot...

Taiwan

euroPLX 86 Munich

Not Confirmed

Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Contact Supplier

Taiwan

Virtual Booth

Digital Content

Baricitinib

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36030

Submission : 2021-08-04

Status : Active

Type : II

02

Apitoria Pharma Private Ltd

India

euroPLX 86 Munich

Not Confirmed

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

01

Eli Lilly

U.S.A

American Pharma Summit

Not Confirmed

Not Confirmed

08

Natco Pharma

India

American Pharma Summit

India

BioFlorida Conference

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629052200,"product":"BARICITINIB API","address":"","city":"","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"TEHRAN","customer":"NANO FANAVARAN DAROUEI ","customerCountry":"IRAN","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"28577.4","totalValueFC":"5552.3","currency":"USD","unitRateINR":2059000,"date":"16-Aug-2021","totalValueINR":"411800","totalValueInUsd":"5552.3","indian_port":"BOMBAY AIR","hs_no":"29334900","bill_no":"3887358","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630693800,"product":"BARICITINIB IN-HOUSE","address":"8-3-166\/7\/1, HETERO HOUSE,\\r\\nERRAGADDA,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"BAGDAD, METROPOLITAN","customer":"M\/S: SAMA ALFAYHAA PHARMACEUTICAL","customerCountry":"IRAQ","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"27000","totalValueFC":"13092","currency":"USD","unitRateINR":1926000,"date":"04-Sep-2021","totalValueINR":"963000","totalValueInUsd":"13092","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"4351673","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAQ","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,\\r\\nERRAGADDA,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645381800,"product":"BARICITINIB IH","address":"H.NO.8-3-166\/7\/1, HETERO HOUSE, ERRAGADDA Contact No: 919396743330","city":"HYDERABAD","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"M\/S.EUROPEAN EGYPTIAN","customerCountry":"EGYPT","quantity":"0.55","actualQuantity":"0.55","unit":"KGS","unitRateFc":"23000","totalValueFC":"12487.2","currency":"USD","unitRateINR":1701818.1818181816,"date":"21-Feb-2022","totalValueINR":"936000","totalValueInUsd":"12487.2","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"8395253","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO.8-3-166\/7\/1, HETERO HOUSE, ERRAGADDA Contact No: 919396743330, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676399400,"product":"CS-T-48553 \/ BARICITINIB","address":"17 LOTUS BUSINESS PARK,NEW LINK RD ANDHERI W","city":"MUMBAI,MAHARASHTRA","supplier":"CLEARSYNTH LABS LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"HELICON","customerCountry":"RUSSIA","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"288","totalValueFC":"2821.2","currency":"USD","unitRateINR":23300,"date":"15-Feb-2023","totalValueINR":"233000","totalValueInUsd":"2821.2","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"7817406","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"17 LOTUS BUSINESS PARK,NEW LINK RD ANDHERI W, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689791400,"product":"BARICITINIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHANGHAI","customer":"TO THE ORDER OF","customerCountry":"CHINA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"35000","totalValueFC":"6874.4","currency":"USD","unitRateINR":2825001.2699999996,"date":"20-Jul-2023","totalValueINR":"565000.254","totalValueInUsd":"6874.4","indian_port":"HYDERABAD AIR","hs_no":"29334900","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1696012200,"product":"BARICITINIB (OTHER) (TAX INV MH1160000298 DT.29.09.2023)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"MARPHINDS","customerCountry":"EGYPT","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"24","totalValueFC":"4686.3","currency":"USD","unitRateINR":1945,"date":"30-Sep-2023","totalValueINR":"389000","totalValueInUsd":"4686.3","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"4327712","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1700073000,"product":"BARICITINIB (TAX INV MH1160000300 DT29.09.2023)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"ALANPHINUDS","customerCountry":"EGYPT","quantity":"3.65","actualQuantity":"3.65","unit":"KGS","unitRateFc":"19000","totalValueFC":"68499.3","currency":"USD","unitRateINR":1562739.7260273972,"date":"16-Nov-2023","totalValueINR":"5704000","totalValueInUsd":"68499.3","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"5366453","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1700159400,"product":"BARICITINIB (OTHER) LUT(ARN)NO AD270323055216A DT 27\/03\/2023)(TAX INV MH1160000301 DT29.09.2023)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"HIPHSA","customerCountry":"EGYPT","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"21060","totalValueFC":"62362.7","currency":"USD","unitRateINR":1731000,"date":"17-Nov-2023","totalValueINR":"5193000","totalValueInUsd":"62362.7","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"5384824","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708367400,"product":"BARICITINIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ULKAR HOLDING","customerCountry":"TURKEY","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"45000","totalValueFC":"2159.8","currency":"USD","unitRateINR":3584180,"date":"20-Feb-2024","totalValueINR":"179209","totalValueInUsd":"2159.8","indian_port":"Hyderabad Air","hs_no":"29334900","bill_no":"7681340","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708453800,"product":"BARICITINIB","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"YANGON","customer":"ALIDAC HEALTHCARE MYANMAR ","customerCountry":"MYANMAR","quantity":"0.70","actualQuantity":"0.7","unit":"KGS","unitRateFc":"21639.3","totalValueFC":"14941.9","currency":"USD","unitRateINR":1771117.6000000001,"date":"21-Feb-2024","totalValueINR":"1239782.32","totalValueInUsd":"14941.9","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"7725664","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MYANMAR","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709058600,"product":"BARICITINIB","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"YANGON","customer":"ALIDAC HEALTHCARE MYANMAR ","customerCountry":"MYANMAR","quantity":"0.70","actualQuantity":"0.7","unit":"KGS","unitRateFc":"21639.3","totalValueFC":"14930","currency":"USD","unitRateINR":1769708.4571428571,"date":"28-Feb-2024","totalValueINR":"1238795.92","totalValueInUsd":"14930","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"7893739","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MYANMAR","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710959400,"product":"BARICITINIB (OTHER) (TAX INV# MH1160000609 DT:06.03.2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"HIPHSA","customerCountry":"EGYPT","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"21060","totalValueFC":"103778.2","currency":"USD","unitRateINR":1723460.2559999998,"date":"21-Mar-2024","totalValueINR":"8617301.28","totalValueInUsd":"103778.2","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"8504319","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719426600,"product":"BARICITINIB","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHANGHAI - PU DONG","customer":"KUNSHAN ROTAM REDDY ","customerCountry":"CHINA","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"29268","totalValueFC":"273.5","currency":"USD","unitRateINR":2283010,"date":"27-Jun-2024","totalValueINR":"22830.1","totalValueInUsd":"273.5","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"2001431","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724783400,"product":"BARICITINIB (OTHER) (TAX INV# MH2411600229 DT:17.08.2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"HONG KONG","customer":"WILISIN CO. LIMITED","customerCountry":"HONG KONG","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"13250","totalValueFC":"14197.7","currency":"EUR","unitRateINR":1190883.74,"date":"28-Aug-2024","totalValueINR":"1190883.74","totalValueInUsd":"14197.7","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"3542038","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"HONG KONG","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""}]